*Sponsored by Lifewater Media. Please see disclosures below.
| Reasons to Watch "CTXR" This Morning... | Hey Folks,
CTXR released big news this morning... |  | "The preliminary results from this Phase I trial of patients with recurrent gynecological cancers are highly encouraging. This novel chemo-free immunomodulatory combination regimen has been well tolerated, including at the highest dosage. This efficacy data strongly suggests that LYMPHIR may have the ability to improve and prolong the anti-tumor activity of immune checkpoint inhibitors. To date, this unique regimen has not been associated with significant immune-related adverse events. Moreover, of the 15 evaluable patients, one third experienced a clinical benefit with a median of more than 12 months of progression free survival," stated Dr. Myron Czuczman, Chief Medical Officer of Citius Pharmaceuticals and Citius Oncology.
Here are five reasons why you should pay attention to CTXR this morning...
1. FDA Approval of LYMPHIR: The company's immunotherapy, LYMPHIR, recently received FDA approval for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL), marking a significant milestone in their product portfolio.
2. Inclusion in NCCN Guidelines: LYMPHIR's addition to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines underscores its clinical value and may enhance its adoption among healthcare providers.
3. Pipeline Progress: The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, which has achieved primary and secondary endpoints in a Phase 3 trial, indicating potential for future FDA approval.
4. Market Potential: With LYMPHIR targeting a niche market in CTCL treatment, Citius has the opportunity to capture a significant share in this specialized oncology segment.
5. Collaborative Opportunities: The company's innovative therapies may attract partnerships or licensing agreements, potentially accelerating market entry and revenue generation.
Anyways...
That's all for now!
Until Next Time,
-Damian | Want our text alerts? Text "ALERT" to 1-(888)-670-9763 to sign up!
(standard carrier data/text rates apply) | *Sponsored by Lifewater Media. Please see disclosures below.
| InsiderOwl is a financial newsletter powered by ZipTrader that offers insight into the latest insider trades. This includes CEOs, CFOs, Big Money Institutions, Politicians, and More.
*SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated nineteen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) on November 11, 2024. ZipTrader may receive additional campaigns in the future by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR). ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) from August 4, 2024 to August 5, 2024. ZipTrader has been compensated twenty thousand USD by ACH Bank Transfer by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR) on January 25, 2023. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Oncology Inc.* (CTOR) on September 23, 2024. As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Citius Pharmaceuticals Inc. (CTXR). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Citius Pharmaceuticals Inc. (CTXR), increased trading volume, and possibly an increased share price of Citius Pharmaceuticals Inc. (CTXR), which may or may not be temporary and decrease once the marketing arrangement has ended.
*Citius Oncology Inc. (CTOR) is a subsidiary of Citius Pharmaceuticals Inc. (CTXR)
BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors.
| Want To Stop Receiving Emails from InsiderOwl? |
ZipTrader LLC 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA | | | | |
